BiomX Inc. (PHGE) 주식 분석

회사 개요

BiomX Inc. (PHGE) operates as a clinical-stage biopharmaceutical entity dedicated to developing phage-based therapies that utilize natural and engineered bacteriophage technologies to specifically target and eliminate harmful bacteria linked to chronic diseases. This business model places the company firmly within the Healthcare sector, specifically the Biotechnology industry, positioning it as a potential innovator in precision medicine solutions for infectious disease management. The company currently maintains a relatively small operational scale with a market capitalization of $7.36 million and employs approximately 20 staff members to advance its therapeutic pipeline. The limited market cap and lack of reported annual revenue figures indicate that BiomX is an early-stage development company focused on research and development rather than commercial revenue generation, which is typical for clinical-stage biopharmaceutical firms before product approval and widespread market entry.

재무 건전성

The company reports a Net Income of $-36,199,000 for the trailing twelve months, while Revenue and EBITDA are not disclosed in the available data, suggesting a significant gap where costs far exceed any generated income. The absence of positive Revenue relative to the substantial Net Income loss reveals a cost structure dominated by heavy investment in clinical trials, research personnel, and operational expenses typical of the biotechnology sector. BiomX's Free Cash Flow stands at $-14,071,500, indicating a net outflow of cash that reflects the capital-intensive nature of drug development and limits immediate financial flexibility for expansion without external financing. All three key margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability on its sales or operational activities due to its developmental stage. The balance sheet shows a Cash position of $4.36 million against a Debt obligation of $1.44 million, yet the Debt to Equity ratio is listed as N/A, likely due to the company's equity structure or negative equity position. While the absolute cash reserves appear positive, the liquidity situation is constrained by the Current Ratio of 0.87, which is below the standard threshold of 1.0 and indicates that current liabilities exceed current assets, potentially creating short-term liquidity pressure. Furthermore, the Return on Equity is reported at -316.9% and the Return on Assets at -78.9%, metrics that clearly reveal management has not yet been effective in generating positive returns on the capital invested by shareholders or the company's asset base.

밸류에이션 평가

Trailing P/E and Forward P/E ratios are presented as N/A and -0.36 respectively, implying that the company does not yet generate positive earnings to support a traditional valuation multiple and that future earnings expectations remain speculative. The Price to Book ratio is listed at -0.37, a negative figure that indicates the market valuation is below the company's book value, often seen in distressed or pre-revenue biotech firms where intangible assets outweigh tangible ones. The Price to Sales ratio is N/A and the EV/EBITDA is -0.82, suggesting that alternative valuation metrics are also skewed by the lack of positive earnings and sales, making standard comparative valuation methods difficult to apply. The stock has traded between a 52-Week High of $14.71 and a 52-Week Low of $1.50, with the current trading price situated significantly below the recent peak, reflecting high market volatility and investor caution regarding the company's near-term commercial prospects. The Beta value of 1.70 indicates that the stock price is substantially more volatile than the broader market, moving with greater intensity to price swings in the overall equity market.

Growth & Income

Revenue Growth and Earnings Growth for the year-over-year period are both listed as N/A, meaning there is no historical data available to determine if earnings are growing faster or slower than revenue at this stage of the company's lifecycle. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute cash to shareholders and instead retains all available capital to reinvest into its research and development initiatives. This reinvestment strategy is characteristic of clinical-stage biopharmaceutical companies that must allocate resources to progress their drug candidates through regulatory approval processes rather than rewarding investors with income distributions. Consequently, the overall growth and income profile of BiomX Inc. is defined entirely by the potential for future commercialization of its phage-based therapies rather than current revenue expansion or dividend income generation.